Clinical trial
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute…
NCT00077493 · MedImmune LLC, Industry · Suspended
Key facts
| NCT number | NCT00077493 |
|---|---|
| Title | BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma |
| Official title | Pediatric Phase I Trial of BL22 for Refractory CD22-Positive Leukemias and Lymphomas |
| Lead sponsor | MedImmune LLC, Industry |
| Collaborators | Cambridge Antibody Technology |
| Status | Suspended |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | BL22 immunotoxin, antibody-drug conjugate therapy, immunotoxin therapy, monoclonal antibody therapy |
| Enrollment | 95 |
| Start date | Jan 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Feb 12, 2004 |
| Last update posted | Dec 28, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: